Our latest

News

Cellvizio® Now Recommended in New European Society of Gastrointestinal Endoscopy Technical Guideline for Pancreatic Cyst Diagnosis

Cellvizio® Now Recommended in New European Society of Gastrointestinal Endoscopy Technical Guideline for Pancreatic Cyst Diagnosis

Mauna Kea Technologies Announces Promising Results in New Application Combining Robotics and Cellvizio® for Precision Surgery in Head and Neck Cancers 

Mauna Kea Technologies Announces Promising Results in New Application Combining Robotics and Cellvizio® for Precision Surgery in Head and Neck Cancers 

Mauna Kea Technologies Secures Additional U.S. Artificial Intelligence Patent to Strengthen Endomicroscopy IP Complex 

Mauna Kea Technologies Secures Additional U.S. Artificial Intelligence Patent to Strengthen Endomicroscopy IP Complex 

Mauna Kea Technologies Reports Full Year 2024 Sales and Provides Strategic Update 

Mauna Kea Technologies Reports Full Year 2024 Sales and Provides Strategic Update 

Mauna Kea Technologies Announces its 2025 Financial Calendar

Mauna Kea Technologies Announces its 2025 Financial Calendar

Raising Pancreatic Cancer Awareness Through Patient Voices 

Raising Pancreatic Cancer Awareness Through Patient Voices 

Mauna Kea Technologies Celebrates Over 700 Procedures Performed in 18 Months at IECED-OMNI Hospital in Ecuador 

Mauna Kea Technologies Celebrates Over 700 Procedures Performed in 18 Months at IECED-OMNI Hospital in Ecuador 

Mauna Kea Technologies Announces Review of Strategic Alternatives 

Mauna Kea Technologies Announces Review of Strategic Alternatives 

Mauna Kea Technologies Provides an Update on Its Recent Developments

Mauna Kea Technologies Provides an Update on Its Recent Developments

Mauna Kea Technologies Announces New Positive Clinical Results for Cellvizio in Food Intolerance

Mauna Kea Technologies Announces New Positive Clinical Results for Cellvizio in Food Intolerance

Mauna Kea Technologies Reports H1 2024 Financial Results and Q3 2024 Sales  

Mauna Kea Technologies Reports H1 2024 Financial Results and Q3 2024 Sales  

Mauna Kea Technologies Announces Ground-Breaking Positive Clinical Results in Lung Cancer Obtained with Cellvizio 

Mauna Kea Technologies Announces Ground-Breaking Positive Clinical Results in Lung Cancer Obtained with Cellvizio